You are here

  • Home
  • Archive
  • Volume 102, Issue Suppl 6
  • 36 Triple Therapy Anticoagulation following Percutaneous Coronary Intervention (PCI) with Novel Oral Anticoagulants (NOAC) is Safe and has no Adverse Effects on Bleeding Post Procedure when Compared to Triple Therapy with Vitamin K Antagonist (VKA)

Article info

Article menu

Download PDFPDF

Heart View
Interventional Cardiology
36 Triple Therapy Anticoagulation following Percutaneous Coronary Intervention (PCI) with Novel Oral Anticoagulants (NOAC) is Safe and has no Adverse Effects on Bleeding Post Procedure when Compared to Triple Therapy with Vitamin K Antagonist (VKA)
Free

Authors

Citation

Amin R, McWilliams N, Lee D, et al
36 Triple Therapy Anticoagulation following Percutaneous Coronary Intervention (PCI) with Novel Oral Anticoagulants (NOAC) is Safe and has no Adverse Effects on Bleeding Post Procedure when Compared to Triple Therapy with Vitamin K Antagonist (VKA)
Heart 2016;102:A25-A26.

Publication history

  • First published June 3, 2016.
Online issue publication 
January 18, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions